![]() ![]() Refer to Recommendations for use, Children for more information. A complete primary series with an mRNA COVID-19 vaccine may be offered to children 6 months to less than 5 years of age and should be offered to children 5 to 11 years of age without contraindications to the authorized vaccine, with a dosing interval of at least 8 weeks between the first and second dose.Refer to Safety and adverse events for more information. Serious adverse events following immunization can occur very rarely.These side effects may include: pain, redness and swelling at the injection site, axillary (or groin) swelling or tenderness, fatigue, headache, muscle pain, chills, joint pain, and fever. However, they are mild or moderate and transient, resolving within a few days. For all vaccines, some adverse events are reported to be very common (defined as 10% or more) among vaccine recipients.Refer to Preparations authorized for use in Canada for more information. These include messenger ribonucleic acid (mRNA) vaccines, protein subunit and virus-like particle (VLP) vaccines, and non-replicating viral vector vaccines. Several vaccines for COVID-19 had been authorized for use in Canada since December 2020.However, some populations are at increased risk of exposure to the virus due to living or occupational settings and some populations are at increased risk of severe outcomes due to biological and/or social factors. Anyone can be infected with SARS-CoV-2.Novel coronavirus disease 2019 (COVID-19) is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).Key information (refer to text and tables for details) What Blood products, human immunoglobulin and timing of immunization.Tuberculin skin testing (TST) and interferon gamma release assay (IGRA).Guidance on reporting adverse events following immunization (AEFI).Uncommon, rare and very rare adverse events.Concurrent administration with other vaccines.Suggested intervals between previous SARS-CoV-2 infection and COVID-19 vaccination ![]() Individuals previously infected with SARS-CoV-2.Table 4: Pregnancy registry information by vaccine product.Summary table of mRNA COVID-19 booster doses by age group Immunization schedule and minimum intervals for a primary series for moderately to severely immunocompromised individuals, by COVID-19 vaccine Immunization schedule for a primary series, by COVID-19 vaccine Immunogenicity, efficacy and effectiveness.Preparations authorized for use in Canada.Update to previous recommendations on the use of Novavax Nuvaxovid COVID-19 vaccine as a primary series and as a booster dose in adults (18 years of age and older)įor more information, refer to the Canadian Immunization Guide (CIG) Summary.Recommendations on the use of Novavax Nuvaxovid COVID-19 vaccine as a primary series in adolescents (12 to 17 years of age).Recommendations on the use of Moderna bivalent BA.1 and BA.4/5 as a booster dose in individuals 6 to 17 years of age. ![]() This chapter was updated based on the following guidance from the National Advisory Committee on Immunization (NACI):
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |